24 May

HealthBeacon Obtains FDA Clearance for the World’s First Smart Sharps Adherence Device

Digital Therapeutic company HealthBeacon receives 510K FDA clearance to provide smart sharps bins to US patients

(Dublin, Ireland; Boston, MA) HealthBeacon, a digital therapeutic innovator, announced today that they have received clearance by the United States Food and Drug Administration (FDA) to offer the HealthBeacon smart sharps bin to patients using injectable medications in the US.

HealthBeacon’s injectable adherence platform has been cleared by the FDA, and will be available for the first time to the millions of Americans on long term, chronic injectable care. HealthBeacon anticipates the US commercial launch of its platform later this summer.

Since launching commercially in Europe, in 2013, HealthBeacon currently serves thousands of patients across 10 markets in Canada, Europe, the Middle East and South America.

HealthBeacon CEO, Jim Joyce, has stated, “Working with the FDA over the last year, and ultimately receiving FDA clearance is a defining moment for HealthBeacon as a company. We are excited to launch in the US later this summer.”

The digital therapeutic market has reached significant landmarks in the last year, and HealthBeacon joins a small but elite number of digital therapeutic organizations with validated technology that have received FDA clearance.

Robert K. Coughlin, President and CEO of MassBio has commented, “I am delighted to hear HealthBeacon has received FDA Clearance for their novel medical technology, and has chosen Boston to launch their U.S. operations. There is no better place in the world for the life sciences, and we’re thrilled to welcome a company that will bring further value to the healthcare system and to patients.”

Dublin, Ireland based HealthBeacon has strong ties to the US, as it is founded by Irish-American and native Bostonian Jim Joyce. This connection has strengthened since opening their first US based office in Boston in March of 2017.

This clearance is part of HealthBeacon’s regulatory strategy to make its technology available globally. This follows on HealthBeacon’s recent announcement of approval for the Brazilian market.

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.

12 Apr

Digital Therapeutic Innovator HealthBeacon receives full regulatory approval for the Brazilian market

(DUBLIN, SAO PAOLO, April 12, 2018) HealthBeacon announced today that it has completed the regulatory process to launch their smart sharps bin and digital therapeutic platform into Brazil. Approval for marketing by both the telecom and health regulators opens HealthBeacon to service the millions of patients on injectable medications in Brazil. Following great success in Europe and North America, HealthBeacon’s Brazilian partners are enthusiastic about presenting this innovative technology through their patient support programmes.

HealthBeacon is the market leader in tracking adherence for injectable medications and has already launched into 8 countries in Europe and North America. Thousands of patients in these markets are showing double digit increases in adherence versus patients without connected medicines.

Due to the size of Brazil, supporting patients who are far away from hospital is a key priority in improving outcomes of community health. HealthBeacon entering this market represents an advancement in care for patients on chronic injection therapies used in the home. HealthBeacon CEO Jim Joyce said about the launch in Brazil,

“We’ve been working on preparing for the Brazilian market over the last year. Our strategy is to make our technology available globally we are excited to make the HealthBeacon available in such an important market.”

Back in October, HealthBeacon hosted Brazilian insurance influencers in our Dublin office to participate in a workshop to explore the opportunities afford in Brazil and the enthusiasm was resounding.

Brazil is a major market with millions of patients and is a key country in HealthBeacon’s global expansion strategy.  The Brazil launch will represent the first market in Latin America with additional LATAM markets implementing shortly. HealthBeacon’s global expansion includes entering another 8 countries across Europe, North America and Latin America in 2018.

The Latin American team is headed up by Regional Manager Andrea Rangel, based in Sao Paulo, Brazil. The HealthBeacon will be available to patients in Brazil over the coming months.

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.


(DUBLIN, SÃO PAULO, 12 de abril de 2018) HealthBeacon anunciou hoje que concluiu o processo de regulamentação para o lançamento de sua plataforma terapêutica inteligente e digital no Brasil. A aprovação para comercialização pelos reguladores de telecomunicações e de saúde abre o HealthBeacon para atender aos milhões de pacientes com medicamentos injetáveis ​​no Brasil. Após o grande sucesso na Europa e na América do Norte, os parceiros brasileiros da HealthBeacon estão entusiasmados em apresentar essa tecnologia inovadora por meio de seus programas de suporte ao paciente.

A HealthBeacon é líder de mercado no rastreamento da adesão de medicamentos injetáveis ​​e já foi lançada em oito países da Europa e América do Norte. Milhares de pacientes nesses mercados tem apresentando aumentos de dois dígitos na adesão versus pacientes sem medicamentos conectados.

Devido ao tamanho do Brasil, o suporte a pacientes que estão longe do hospital é uma prioridade fundamental para melhorar os resultados da saúde da comunidade. A entrada da HealthBeacon neste mercado representa um avanço no atendimento aos pacientes em terapias de injeção crônica utilizados em casa. O CEO da HealthBeacon, Jim Joyce, falou sobre o lançamento no Brasil,

“Estamos trabalhando na preparação para o mercado brasileiro desde o ano passado. Nossa estratégia é disponibilizar nossa tecnologia globalmente e estamos empolgados em disponibilizar o HealthBeacon em um mercado tão importante”.

Em outubro, a HealthBeacon trouxeos influenciadores de seguros brasileiros em nosso escritório em Dublin para participar de um workshop para explorar as oportunidades oferecidas no Brasil e o entusiasmo foi retumbante.

O Brasil é um mercado importante com milhões de pacientes e é um país-chave na estratégia de expansão global da HealthBeacon. O lançamento no Brasil representará o primeiro mercado na América Latina com mercados adicionais LATAM implementando em breve. A expansão global da HealthBeacon inclui a entrada em outros 8 países da Europa, América do Norte, América Latina e África em 2018.

A equipe da América Latina é liderada pela Gerente Regional Andrea Rangel, com sede em São Paulo, Brasil. O HealthBeacon estará disponível para pacientes no Brasil nos próximos meses.

Sobre o HealthBeacon

HealthBeacon é uma empresa de terapêutica digital que desenvolve ferramentas inteligentes para gerenciar medicamentos. A HealthBeacon desenvolveu um sistema de gerenciamento de medicação injetável que monitora os pacientes digitalmente, mantendo-os aderentes às suas prescrições e aproveitando os dados em tempo real para conduzir a intervenção clínica. Esse sistema foi revisado clinicamente, validado pela indústria farmacêutica e integrado a programas de atendimento ao paciente na América do Norte e na Europa, fornecendo dados valiosos para o paciente e sua equipe clínica.

26 Mar

A “Device” For Providing Better Drug Outcomes

HealthBeacon CEO, Jim Joyce was recently interviewed by Bob Marshall, Chief Editor of digital publication, Med Device Online. The interview was featured in the publication highlighting medication adherence issues, and the approach HealthBeacon is taking to reduce medication-related problems. Using data from the Mayo Clinic and the American Journal of Managed Care, Marshall identifies HealthBeacon’s approach to real-world evidence and patient experience.

Read the full article here.

20 Mar

HealthBeacon Announces Winning of Johnson & Johnson Innovation, JLABS Patient Adherence QuickFire Challenge

(Dublin, New York, March 19th, 2018) HealthBeacon announces that is has been chosen as the winner of the Johnson & Johnson Innovation, JLABS and Janssen Supply Chain Group, LLC (JSC) Patient Adherence QuickFire Challenge. The announcement was made at the New York Genome Center, home to the new JLABS @ NYC opening in June 2018, in New York, NY, USA. This challenge was designed to identify companies that are creating innovative solutions for patients, that are easy to use and may be integrated into a patient’s typical daily healthcare routine. HealthBeacon was voted as the overall winner of the challenge and as such will receive a $75,000 award.

HealthBeacon was identified as the winner for displaying excellence in the following categories.

  • High impact on healthcare outcomes and adherence
  • Leap frog innovation & market competitiveness: new methodology & technology feasibility
  • User friendly & ease of implementation
  • Integrated, holistic solution from Pharma manufacturer to patient
  • Commercial scalability


HealthBeacon has a strong understanding of how adherence solutions can be used to improve patient outcomes. HealthBeacon was represented at the event by CTO and Co-Founder Kieran Daly, and Design Director, Kyle Bolton.

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.

20 Feb

HealthBeacon shortlisted for Most Valuable Patient Initiative

HealthBeacon is shortlisted for the eyeforpharma Award, in the Most Valuable Patient Initiative category.

HealthBeacon was selected by a judging panel of pharma industry experts, patients and customers as a finalist. HealthBeacon will be represented at the award presentation by CEO, Jim Joyce. HealthBeacon will present their innovative technology to the judging panel on March 12th. Winners will be announced on 13th of March in Barcelona at eyeforpharma Barcelona in front of industry leaders, patients and other stakeholders.

About eyeforpharma awards

The eyeforpharma awards celebrate positive progress towards value for patients and customers and recognizes those in the pharmaceutical industry that are driving pharma forwards.

We celebrate those who aren’t just chasing higher short-term profits, but who are investing in better customer innovation, value and outcomes leading to longer-term success.

This is part of eyeforpharma’s mission to make the pharmaceutical industry more open and valued, which means these awards are a literal translation of why we exist. It is our responsibility to shine a light on where pharma does well, to inspire others into similar or better action.


About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeps them adherent to their prescription and leverages real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.


Follow us on Twitter @HealthBeaconInc

29 Jan

Sunday Business Post: Prognosis is good for remote medication monitoring

A medtech company’s special bin for patients who self-inject medications at home is one of a range of ‘digital therapeutics’ that could help improve health outcomes for people with illnesses like cancer and rheumatoid arthritis.

Article by Leanna Byrne

In November last year, medtech company HealthBeacon announced it was looking to raise €5 million, to bring its total funding to €8 million. By now, it is €2.5 million into its funding and will launch into another 11 markets by the end of 2018.

These kind of investments are common for companies with the next blockbuster drug or game changing medical device, but HealthBeacon though only four years old, finds itself in one of the hottest new areas in the health sector: Digital Therapeutics. Digital therapeutics, or “digiceuticals,” as some call them have become a Holy Grail in some quarters of Silicon Valley, where investors see the chance to deliver medicine through your smartphone.

How it works is that the app or platform helps treat diseases by modifying patient behaviour and providing remote monitoring to improve long-term health outcomes.

HealthBeacon has developed a special bin for patients who self-inject medications at home. The bin is digitally connected to its technology platform, which helps patients keep to their medication schedule with digital reminders. Equally, healthcare professionals will know whether or not their patients are keeping on track with their meds. “There is no real way of knowing whether someone took their medications other than by asking them,” said Jim Joyce, chief executive of HealthBeacon.

The key difference between digital therapeutics and wellness apps is that HealthBeacon tailors its treatment programmes to specific ailments, like cancer or rheumatoid arthritis. Since patient behaviour is important in preventing and limiting the severity of these illnesses, these digital health programmes, combined with human coaching and interaction, can make a significant difference in health outcomes.

“The whole issue of people doing what the doctor said is pretty well known. If people don’t, then it costs the system a lot of money and it can compromise a lot of people’s health,” said Joyce.

Originally from Boston, Joyce first came to Ireland to work in the pharma industry before he went out on his own in 2006 to start health services company Point of Care. The company specialised in medical and infusion care and worked through a network of community care clinics. Joyce spent 8 years building up Point of Care, where he is still a director. But Point of Care’s work led him to notice the patients who were on injectable medications and were administering their own medication at home.

“The idea for HealthBeacon was that we took this medical waste bin and turned it into a digital healthcare assistant. We encased a traditional waste bin and can give information about the place and time to take your medication. If you take it, we know from the disposal of the injection into the box. If you don’t take it, that information goes to your healthcare provider,” said Joyce.

Joyce met Kieran Daly, co-founder of HealthBeacon, when he was chief executive at Shimmer and asked him to take a look at his idea. The next step was to get regulated and to test the product with early pilots in pharma companies in Ireland. Next came global pilots in ten markets, which led to big contracts with pharma companies.

“We’re now at a stage where we’ve got the product pretty well penetrated in the Irish setting. We’ve launched it into eight different countries, from Canada to throughout Europe. Then we’ll be into another 11 markets by the end of 2018 as per the agreements that we have, including the US,” said Joyce.

The €5 million funding round is expected to be closed by March, while HealthBeacon’s FDA approval is expected to come in Q1 this year.  The company, which employs 20 staff in Dublin, also has offices in Boston and Montreal and will add another 20 staff across these locations.

“Getting the US market launch is probably the number one resource. We’ve got lots of ideas for new products that we want to start working on. We want to move beyond just injectable medications into pills and some other areas,” said Joyce.

HealthBeacon is also planning to enter Mexico and Brazil by the first half of this year, with a long-term focus on Latin America.

But even though Joyce believes the only way to hit critical numbers is to look outside Ireland, he views what companies are now doing in the Irish medtech industry as very exciting. “I definitely see more activity in medical technology and the digital health area. It’s still kind of emerging. I see lots of interesting companies. It’s a good time,” said Joyce. “We were able to get really deep market penetration in Ireland, in order to show people the product worked, which would have been harder if we were in Britain or the US.”


23 Jan

A Random Encounter for Digital Therapeutics

HealthBeacon President of Partnerships, Dave Shanahan was part of the HealthBeacon team that participated in the JP Morgan Healthcare Conference in San Francisco in mid-January. This event brought together biopharmaceutical industry executives and digital therapeutic innovators from all over the world, and led to an educational encounter between Dave and Rob Wright, Chief Editor of Life Science Leader online magazine.

Wright, wrote about the encounter as part of a blog series on the conference entitled “Connectivity- The Beauty of JPM and BTS”. He writes, “one of the more intriguing experiences took place at the Biotech Showcase. Grabbing a quick breakfast, I sit down at a table occupied by Dave Shanahan, president of partnerships for HealthBeacon, a medication-adherence technology company based in Dublin, Ireland. Shanahan gets me up to speed on the company’s first product, a smart sharps bin, as well as their current project, a tool to help automate medication compliance. According to Shanahan, there are over two billion cases of poor medication adherence each year, which costs patients and societies about $290 billion — annually! “The most expensive medication is the one not taken,” he notes. With the push by insurance companies and governments to provide better patient outcomes, it seems HealthBeacon has landed on some simple solutions that might help.”

Events like the JP Morgan conference bring together influential thought leaders from all over the world. Meetings of these industry leaders will help drive real world evidence of connected medicine and redefine the future of Digital Therapeutics.

Read the full article


07 Jan

HealthBeacon to Present at JP Morgan Conference

(Dublin, Ireland) HealthBeacon Ltd., a privately held and innovative connected
medicine company, announced today that Chief Executive Officer Jim Joyce, is scheduled to
present during the JP Morgan Conference at both the Biotech Showcase and the Digital
Medicine Showcase. The conference takes place in San Francisco from January 8th to January
10th .
HealthBeacon’s presentation times and venues:

  • Biotech Showcase on Tuesday, January 9th , 2018 at the Hilton San Francisco Union
    Square, 333 O’Farrell Street at 1:45pm (PST) – Franciscan A Ballroom Level.
  • Digital Medicine & Medtech Showcase on Wednesday, January 10th , 2018 at the hotel
    Parc 55 San Francisco at 2:15 pm (PST) – 4th Floor Magnin III


About HealthBeacon: The company headquartered in Dublin, Ireland with offices in Boston and
Montreal was established by serial medical technology entrepreneurs, Jim Joyce (CEO) and
Kieran Daly (CTO) to address an opportunity to use digital health technology to target the
medical adherence of high value medications. HealthBeacon’s award winning “smart sharps
solution”, connected via Internet of Things (IoT) technology, addresses medical adherence for
patients on chronic injection therapy in conditions like Diabetes, Multiple Sclerosis, Rheumatoid
Arthritis, Crohn’s Disease, in addition to various respiratory conditions. HealthBeacon has moved
at high velocity from concept to global roll-out in only four years. The solution is already available
and operating in 8 countries, in conjunction with major Pharma companies and is launching into
an additional 11 countries in 2018. HealthBeacon’s application for FDA clearance was submitted in August 2017, with anticipated US commercial availability in Q1 2018.

Follow us on
Twitter: https://twitter.com/healthbeaconinc
LinkedIn: https://ie.linkedin.com/company/healthbeacon

Brie Kelly, brie@healthbeacon.com

22 Nov

HealthBeacon Announces New Round of Investment Funding

Dublin based med tech company, HealthBeacon, this morning announced the company is embarking on a new round of investment funding seeking €5m before 2018 year end.

The announcement was made at “Investing in Digital Health” a major private investor event hosted by the digital health company earlier this morning. The breakfast event in Royal College of Physicians gathered authorities from medical tech, med entrepreneurs, investment trailblazers and medical experts from all over Ireland.

A keynote presentation regarding “Emerging Trends and impact of Digital and Connected Heath” was delivered by Chandana Fitzgerald, Medical Lead, HealthXL.

HealthBeacon designed “Investing in Digital Health” to bring together some of the most forward thinking technology and healthcare minds to discuss the growth and opportunity for investing in digital health around the panel discussion on ‘Emerging trends and impact of connected health’ – from a Global Perspective.

‘We believe that investing in Digital Health not only substantially improves patient outcomes and delivers a return for national health systems, it creates new employment and investor returns also. Ireland is building on its reputation in the Life Sciences and Medtech arenas by now producing quality Digital Health companies such as Health Beacon that are capable of competing Internationally. We see this as a major area of interest going forward.’ Liam Kiely of Cantor Fitzgerald

Event panellists, led by Mike Ryan, Founding Director of Irrus Investments as panel moderator included Jim Joyce CEO HealthBeacon, Conor Hanley, CEO, Fire1 and Rosanne Longmore, CEO Coroflo who were recently awarded €250,000 from Enterprise Ireland and successfully raised €900,000 within its first six months.

We are excited to announce HealthBeacon’s next investment phase, as we continue to move towards global connection of healthcare through assisting in clever patient medication management and revolutionizing medication adherence.   Our technology provides powerful insights for medics by providing real world patient data.  Jim Joyce, CEO, HealthBeacon

To date HealthBeacon has raised over €3m with current investors including Elkstone Partners and Oyster Capital.

HealthBeacon were recently awarded ‘Pharma Project of the Year – Large’ at the Pharma Industry Awards 2017.  HealthBeacon announced the creation of 20 new jobs for the Dublin based digital health earlier this year.

The “Smart Sharps System” helps patients adhere to their medication schedule. Current estimated costs to manage medication non-adherence is estimated to be $290 billion in the US market alone. The use of HealthBeacon smart technology aims to make a dramatic impact to cost savings within the healthcare industry. The expansion of the platform will provide access to the technology globally in Europe, North America, South America and the Middle East.

24 Oct

Funding and Scaling Series

HealthBeacon CEO, Jim Joyce participated in a “fire side chat” at an investment event for the “Funding and Scaling Series” in Dublin on Tuesday. The event is being hosted by Dublin Business Innovation Centre (Dublin BIC) which provides business consultancy services to early stage, high potential start-ups.

As a serial entrepreneur, Jim was asked to present to the crowd of 300-400 attendees comprised of entrepreneurs, investors and business leaders due to his success in raising funds as HealthBeacon has successfully completed two rounds of funding in the last three years and will be seeking a third round of funding in the coming months.

The event is part of the Dublin BIC Funding and Scaling series, a quarterly breakfast briefing, which was introduced by Dublin BIC in November last year. These briefings offer entrepreneurs the opportunity to explore different approaches to fundraising and scaling for start-ups. It involves hearing the perspectives of investors and learning from those that have successfully funding and scaled their business.

In addition to the presentation regarding his own success, from start-up to scale-up, Jim will join a panel of entrepreneurial peers to answer questions that prepare start-ups for potential investment.

© 2015 Health Beacon - Privacy Policy - Website by Medusa